When assessing the market potential for induced pluripotent stem cells (iPSCs), it is important to consider where the research began, when it accelerated, and where it is at the current point in time.
Timeline of Key iPSC Production Events
The following is a timeline of the key events in the production of iPSCs, beginning with their discovery in 2006. For research product companies interested in dominating the iPSC products marketplace, it is critical to understand the different production methods for iPSCs, the chronological order of the introduction of methodologies, and the inventors who first performed each.
The reason for this is several-fold:
- Research products utilizing the older methods of iPSC production tend to have more companies offering competing products, because a longer timeline for product development has existed.
- Researchers are more likely to prefer to use progressive methods of iPSC generation.
- In most cases, the original inventor of the technique has applied for (and likely been awarded) patent rights that could limit the production of commercial products with that technique, unless a non-exclusive licensing agreement is signed.
As such, research product companies entering the iPSC product marketplace need to be well-informed of the relative timing and progression of induced pluripotent stem cell production methodologies.
Click to enlarge image to full-size.
Future Posts about the Stem Cell Industry
To receive future posts about the stem cell industry, sign-up here. We will never share your information with anyone, and you can opt-out at any time. No spam ever, just great stuff.
About Us
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, and the California Institute for Regenerative Medicine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.
To learn more about emerging opportunities and threats within the iPSC market, view the global strategic report “Complete 2015-16 Induced Pluripotent Stem Cell Industry Report” ” now.
